Nektar Therapeutics (OQ:NKTR)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for NKTR within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 21st, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 20/20 Feb 18/20 Zalevsky Jonathan Direct Ownership Common Stock S - Open market or private sale -4,774 $22.35
Feb 20/20 Feb 18/20 Thomsen Jillian B. Direct Ownership Common Stock S - Open market or private sale -1,394 $22.35
Feb 20/20 Feb 18/20 Robin Howard W Direct Ownership Common Stock S - Open market or private sale -8,448 $22.35
Feb 20/20 Feb 18/20 Labrucherie Gil M Direct Ownership Common Stock S - Open market or private sale -5,938 $22.35
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -8,000  
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Common Stock S - Open market or private sale -3,599 $23.72
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Common Stock S - Open market or private sale -4,401 $23.32
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 -8,000 $9.24
Feb 7/20 Feb 6/20 Thomsen Jillian B. Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -37,500  
Feb 7/20 Feb 6/20 Thomsen Jillian B. Direct Ownership Common Stock S - Open market or private sale -37,500 $22.78
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for NKTR within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 21st, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 20/20 Feb 18/20 Zalevsky Jonathan Direct Ownership Common Stock S - Open market or private sale -4,774 $22.35
Feb 20/20 Feb 18/20 Thomsen Jillian B. Direct Ownership Common Stock S - Open market or private sale -1,394 $22.35
Feb 20/20 Feb 18/20 Robin Howard W Direct Ownership Common Stock S - Open market or private sale -8,448 $22.35
Feb 20/20 Feb 18/20 Labrucherie Gil M Direct Ownership Common Stock S - Open market or private sale -5,938 $22.35
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -8,000  
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Common Stock S - Open market or private sale -3,599 $23.72
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Common Stock S - Open market or private sale -4,401 $23.32
Feb 14/20 Feb 12/20 Chess Robert Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 -8,000 $9.24
Feb 7/20 Feb 6/20 Thomsen Jillian B. Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -37,500  
Feb 7/20 Feb 6/20 Thomsen Jillian B. Direct Ownership Common Stock S - Open market or private sale -37,500 $22.78
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $NKTR

Competitors

Competitors with Recent Insider Filings
Iqvia Holdings (N:IQV)
Alnylam Pharmaceuticals (OQ:ALNY)
Vir Biotechnology (OQ:VIR)